LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of ...
Barnett will retire effective April 1, and Jennifer Pasquali, currently CFO/COO, will take over as president and CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback